- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04057118
A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.
October 8, 2020 updated by: Oscotec Inc.
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies
This study will evaluate the safety and efficacy of SKI-O-703 compared with placebo, in patients with active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying agents.
Patients will be randomly assigned to one of 4 groups and will receive one of three doses of SKI-O-703 or placebo, administered orally twice daily for 12 weeks.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
148
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ostrava, Czechia, 702 00
- Oscotec Investigational Site (Site 2101)
-
Zlín, Czechia, 760 01
- Oscotec Investigational Site (Site 2102)
-
-
-
-
-
Nadarzyn, Poland, 05-830
- Oscotec Investigational Site (Site 2206)
-
-
Dolnoslaskie
-
Wrocław, Dolnoslaskie, Poland, 53-224
- Oscotec Investigational Site (Site 2208)
-
-
Kujawsko-pomorskie
-
Bydgoszcz, Kujawsko-pomorskie, Poland, 85-168
- Oscotec Investigational Site (Site 2204)
-
-
Lubelskie
-
Lublin, Lubelskie, Poland, 20-582
- Oscotec Investigational Site (Site 2207)
-
-
Mazowieckie
-
Warszawa, Mazowieckie, Poland, 01-518
- Oscotec Investigational Site (Site 2202)
-
-
Podlaskie
-
Białystok, Podlaskie, Poland, 15-879
- Oscotec Investigational Site (Site 2201)
-
-
Swietokrzyskie
-
Ostrowiec Świętokrzyski, Swietokrzyskie, Poland, 27-400
- Oscotec Investigational Site (Site 2209)
-
-
Wielkopolskie
-
Poznań, Wielkopolskie, Poland, 61-397
- Oscotec Investigational Site (Site 2203)
-
-
-
-
-
Kemerovo, Russian Federation, 650066
- Oscotec Investigational Site (Site 2307)
-
Moscow, Russian Federation, 119049
- Oscotec Investigational Site (Site 2304)
-
Moscow, Russian Federation, 129110
- Oscotec Investigational Site (Site 2305)
-
Novosibirsk, Russian Federation, 630099
- Oscotec Investigational Site (Site 2308)
-
Ryazan', Russian Federation, 390026
- Oscotec Investigational Site (Site 2306)
-
Saint Petersburg, Russian Federation, 194291
- Oscotec Investigational Site (Site 2302)
-
Saint Petersburg, Russian Federation, 196084
- Oscotec Investigational Site (Site 2303)
-
Tomsk, Russian Federation, 634050
- Oscotec Investigational Site (Site 2301)
-
-
-
-
-
Kharkiv, Ukraine, 61058
- Oscotec Investigational Site (Site 2508)
-
Kyiv, Ukraine, 01023
- Oscotec Investigational Site (Site 2501)
-
Kyiv, Ukraine, 04050
- Oscotec Investigational Site (Site 2503)
-
Kyiv, Ukraine, 4107
- Oscotec Investigational Site (Site 2502)
-
Poltava, Ukraine, 36024
- Oscotec Investigational Site (Site 2507)
-
Vinnytsia, Ukraine, 21009
- Oscotec Investigational Site (Site 2509)
-
-
Ivano-Frankivs'ka Oblast
-
Ivano-Frankivs'k, Ivano-Frankivs'ka Oblast, Ukraine, 76018
- Oscotec Investigational Site (Site 2510)
-
-
Ternopil's'ka Oblast'
-
Ternopil', Ternopil's'ka Oblast', Ukraine, 46002
- Oscotec Investigational Site (Site 2505)
-
-
Vinnyts'ka Oblast'
-
Vinnytsia, Vinnyts'ka Oblast', Ukraine, 21018
- Oscotec Investigational Site (Site 2506)
-
Vinnytsia, Vinnyts'ka Oblast', Ukraine, 21029
- Oscotec Investigational Site (Site 2504)
-
-
-
-
California
-
Beverly Hills, California, United States, 90211
- Oscotec Investigational Site (Site 3110)
-
Upland, California, United States, 91786
- Oscotec Investigational Site (Site 3105)
-
-
Florida
-
Miami Lakes, Florida, United States, 33014
- Oscotec Investigational (Site 3104)
-
Tampa, Florida, United States, 33614
- Oscotec Investigational Site (Site 3112)
-
-
Kentucky
-
Lexington, Kentucky, United States, 40504
- Oscotec Investigational Site (Site 3108)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
- Oscotec Investigational Site (Site 3102)
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Oscotec Investigational Site (Site 3107)
-
-
Texas
-
Carrollton, Texas, United States, 75010
- Oscotec Investigational Site (3106)
-
Houston, Texas, United States, 77034
- Oscotec Investigational Site (Site 3111)
-
Mesquite, Texas, United States, 75150
- Oscotec Investigational Site (Site 3109)
-
San Antonio, Texas, United States, 78229
- Oscotec Investigational Site (Site 3103)
-
Tomball, Texas, United States, 77375
- Oscotec Investigational Site (Site 3101)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must provide written, signed, informed consent.
- Patients must have a diagnosis of Rheumatoid Arthritis (RA) according to American College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against Rheumatism classification, for at least 6 months prior to first administration of study drug.
- Patients must have active RA at screening and baseline (Day 1 of the study).
- Patients who have active disease despite csDMARD (conventional synthetic disease-modifying antirheumatic drugs) therapy for at least 3 months prior to Day 1 of the study.
- Patients must have had an inadequate response to previous anti-TNF⍺ (anti-tumor necrosis factor alpha) biological agent(s) for the treatment of RA and meet the washout period prior to Day 1 of the study.
Exclusion Criteria:
- Patients receiving oral agents, except for medications listed in inclusion criteria for the treatment of RA.
- Patients who have previously received any other or biological agent for the treatment of RA, other than anti-TNF⍺ inhibitor(s).
- Patients who have a current or past history of hepatitis B virus (HBV) infection; positive test for hepatitis C virus (HCV) antibody; positive test for human immunodeficiency virus (HIV); history of or concurrent interstitial pneumonia; acute infection requiring oral antibiotics within 2 weeks, or parenteral injection of antibiotics within 4 weeks prior to first administration of the study drug; other serious infection within 6 months prior to first administration of study drug; recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to first administration of the study drug; past or current granulomatous infections or other severe or chronic infection; positive test for tuberculosis (TB) or other evidence of TB.
- Patients with uncontrolled diabetes mellitus, or uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg).
- Patients with any other inflammatory or rheumatic diseases that could impact the evaluation of the effect of the study drug.
- Patients with a history of malignancy within 5 years prior to first administration of the study drug, except completely excised and cured squamous cell carcinoma, carcinoma of the cervix in situ, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.
- New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled cardiac disease or heart attack within 6 months prior to first administration of the study drug.
- Female patients who are currently pregnant, breastfeeding or planning to become pregnant or breastfeed within 6 months of the last dose of the study drug.
Other protocol-defined inclusion/exclusion criteria could apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Oral administration, twice per day
|
EXPERIMENTAL: SKI-O-703 100 mg
|
Oral administration, twice per day
|
EXPERIMENTAL: SKI-O-703 200 mg
|
Oral administration, twice per day
|
EXPERIMENTAL: SKI-O-703 400 mg
|
Oral administration, twice per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disease activity score
Time Frame: Baseline and Week 12
|
Mean change from baseline in disease activity score for 28 joints (DAS28) using hsCRP (high sensitivity C-reactive protein)
|
Baseline and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Percentage of patients with ACR20 (American College of Rheumatology 20) score
Time Frame: Baseline and Weeks 2, 4 8 and 12
|
ACR20 score is the percentage of patients showing ≥20% improvement from baseline in tender joint count (68 joint counts), ≥20% improvement in swollen joint count (66 joint counts), and ≥20% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)
|
Baseline and Weeks 2, 4 8 and 12
|
• Percentage of patients with ACR50 (American College of Rheumatology 50) score
Time Frame: Baseline and Weeks 2, 4 8 and 12
|
ACR50 score is the percentage of patients showing ≥50% improvement from baseline in tender joint count (68 joint counts), ≥50% improvement in swollen joint count (66 joint counts), and ≥50% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)
|
Baseline and Weeks 2, 4 8 and 12
|
• Percentage of patients with ACR70 (American College of Rheumatology 70) score
Time Frame: Baseline and Weeks 2, 4 8 and 12
|
ACR70 score is the percentage of patients showing ≥70% improvement from baseline in tender joint count (68 joint counts), ≥70% improvement in swollen joint count (66 joint counts), and ≥70% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)
|
Baseline and Weeks 2, 4 8 and 12
|
Health Assessment Questionnaire-Disability Index (HAQ-DI) score
Time Frame: Baseline and Weeks 2, 4 8 and 12
|
Change from baseline measured by disability index
|
Baseline and Weeks 2, 4 8 and 12
|
Incidence of Adverse Events (AEs)
Time Frame: Up to Week 16
|
Up to Week 16
|
|
Incidence of Serious Adverse Events (SAEs)
Time Frame: Up to Week 16
|
Up to Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 20, 2019
Primary Completion (ANTICIPATED)
October 1, 2020
Study Completion (ANTICIPATED)
October 1, 2020
Study Registration Dates
First Submitted
August 13, 2019
First Submitted That Met QC Criteria
August 13, 2019
First Posted (ACTUAL)
August 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
October 12, 2020
Last Update Submitted That Met QC Criteria
October 8, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSCO-P2201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on SKI-O-703
-
Oscotec Inc.CompletedHealthy VolunteersUnited States
-
Oscotec Inc.PPDCompletedRheumatoid ArthritisUnited States
-
Oscotec Inc.PPDCompletedArthritis, RheumatoidUnited States
-
Oscotec Inc.CompletedImmune ThrombocytopeniaUnited States, Greece, Korea, Republic of, Poland, Spain
-
Medikine, Inc.Medikine Australia Pty Ltd.CompletedHealthy VolunteersAustralia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); PfizerTerminatedChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White CellsUnited States
-
BTL Industries Ltd.Unknown
-
BTL Industries Ltd.UnknownObesity | OverweightBulgaria
-
Massachusetts General HospitalPfizer; Dana-Farber Cancer Institute; Brigham and Women's HospitalCompleted
-
China Medical University HospitalMinistry of Science and Technology, TaiwanActive, not recruiting